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Abstract
Background Lubiprostone, a bicyclic fatty acid, is used
for the treatment of chronic constipation. No published
study has addressed the effect of lubiprostone on intestinal
ion secretion in vivo.
Aim The aim of this study was to test the hypothesis that
lubiprostone augments duodenal HCO3
- secretion (DBS).
Methods Rat proximal duodenal loops were perfused
with pH 7.0 Krebs, control vehicle (medium-chain tri-
glycerides), or lubiprostone (0.1–10 lM). We measured
DBS with ﬂow-through pH and CO2 electrodes, perfusate
[Cl
-] with a Cl
- electrode, and water ﬂux using a non-
absorbable ferrocyanide marker. Some rats were pretreated
with a potent, selective CFTR antagonist, CFTRinh-172
(1 mg/kg, ip), 1 h before experiments.
Results Perfusion of lubiprostone concentration depen-
dently increased DBS, whereas net Cl
- output and net
water output were only increased at 0.1 lM, compared
with vehicle. CFTRinh-172 reduced lubiprostone (10 lM)-
induced DBS increase, whereas net Cl
- output was also
unchanged. Nevertheless, CFTRinh-172 reduced basal net
water output, which was reversed by lubiprostone. Fur-
thermore, lubiprostone-induced DBS was inhibited by EP4
receptor antagonist, not by an EP1/2 receptor antagonist or
by indomethacin pretreatment.
Conclusions In this ﬁrst study of the effect of lubipro-
stone on intestinal ion secretion in vivo, lubiprostone
stimulated CFTR-dependent DBS without changing net
Cl
- secretion. This effect supports the hypothesis that Cl
-
secreted by CFTR is recycled across the apical membrane
by anion exchangers. Recovery of water output during
CFTR inhibition suggests that lubiprostone may improve
the intestinal phenotype in CF patients. Furthermore,
increased DBS suggests that lubiprostone may protect the
duodenum from acid-induced injury via EP4 receptor
activation.
Keywords ClC-2  EP receptor  Water secretion 
CFTR  Prostaglandin
Introduction
Chronic constipation is a common clinical problem.
Although most cases do not reach medical attention due to
the plethora of over-the-counter remedies available, severe
constipation can be intractable to most remedies and, in its
severe form, can be debilitating.
Recently, lubiprostone, a bicyclic fatty acid was
approved by the FDA for the treatment of chronic consti-
pation in adults. This compound appears to be in a new
therapeutic class and works by a mechanism that has been
described in only a few publications. In a detailed investi-
gation of the effect of lubiprostone, Cuppoletti et al. tested
the hypothesis that lubiprostone increased the activity of the
chloride channel ClC-2. To test the hypothesis, they dem-
onstrated that ClC-2 was expressed in the stomach and in
the epithelial cells of the small and large intestine by PCR
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apically expressed in transfected intestinal T84 cells.
Electrophysiological measurements in T84 and in ClC-2
transfected human epithelial kidney (HEK) cell monolayers
and in patch-clamped individual cells revealed that lubi-
prostone increased transepithelial and transmembrane cur-
rents in T84 only in ClC-2 transfected cells [1]. These data
suggest that lubiprostone increases Cl
- secretion by acti-
vation of the intestinal epithelial cell ClC-2 channel.
Even given these compelling data, the role of ClC-2
channels in epithelial ion secretion is by no means estab-
lished. First described in 1992 [2], ClC-2 channels are
expressed in the stomach, intestine, colon, brain, heart, and
muscle. They are part of a family of channels and trans-
porters [3], four of which are plasma membrane expressed,
with ClC-2 being the only member to which epithelial
transport function is attributed. Its enterocyte expression is
thought to be mostly basolateral in situ, based on studies
which report localization below the junctional protein
ZO-1 [4–6].
The discovery that the mutations of the cystic ﬁbrosis
transmembrane regulator (CFTR), an epithelial Cl
- chan-
nel, are responsible for the disease phenotype has increased
interest in the function of all epithelial Cl
- channels. With
the discovery of ClC-2 channels, investigators hypothe-
sized that ClC-2 function might compensate for CFTR
loss-of-function, which might explain the lack of overt
pulmonary or pancreatic phenotype in CFTR knockout
(KO) transgenic mice. Studies of ClC-2 KO transgenic
mice revealed that ClC-2 dysfunction actually increased
Cl
- secretion, and that double transgenic mice had a sur-
vival advantage over CFTR mutant mice, data most com-
patible with ClC-2 serving to recycle Cl
- across the
basolateral membrane [7]. Others have implicated ClC-4 in
intestinal Cl
- secretion [8]. Although apical Cl
- channels
are hypothesized to facilitate gastric HCl secretion in
parietal cells, ClC-2 could not be immunolocalized in the
stomach by one group [9], although gastric expression was
documented by another [1].
In one of the few published clinical studies addressing
the intestinal effects of lubiprostone, Camilleri et al. [10]
found that lubiprostone inhibited gastric emptying, but
accelerated small and large intestinal transit, which is
associated with postprandial fullness. Subsequently,
investigators have reported a beneﬁcial effect of lubipro-
stone in subjects with chronic constipation and functional
bowel disease on the basis of clinical trials [11, 12].
To date, one full-length published study has addressed
the effects of lubiprostone on gut ﬂuid secretion. Fei et al.
reported that lubiprostone increased Isc in Ussing-cham-
bered guinea pig distal ileum and colon [13]. Although the
response was unaffected by the neurotoxin tetrodotoxin, or
by EP receptor antagonists, consistent with a non-neurally
and non-prostaglandin mediated mechanism, serosal
application also produced a robust response, calling into
question the role of ClC-2 if it was indeed apically
expressed. Furthermore, the response was also inhibited by
mucosal application of anion channel blockers such as
glibenclamide and DIDS.
Given the aforementioned Ussing chamber studies,
functional conﬁrmation in situ in vivo would help further
understand the effect of the compound on intestinal ﬂuid
secretion. We thus propose to examine the effect of lubi-
prostone on ﬂuid and electrolyte secretion in the duode-
num, a locus of enterocyte anion secretion, with a focus on
HCO3
- secretion, which protects the mucosa from injury
due to luminal acid [14]. Furthermore, given the possible
confounding effect of CFTR-mediated secretion, we intend
to examine the effect of acute CFTR inhibition on duodenal
ﬂuid and electrolyte secretion with a systemic, pharmaco-
logic highly selective CFTR inhibitor.
Methods
Chemicals and Animals
Lubiprostone (10 mg/ml in 0.04% medium-chain triglyc-
erides (MCT) diluent Miglyol 812 N) and vehicle (MCT
diluent alone) was provided from Takeda Pharmaceuticals
North America, Inc. (Deerﬁeld, IL). CFTRinh-172 was
synthesized by Dr. Samedy Ouk in the Department of
Chemistry, UCLA [15]. AH6809, AH23848, indomethacin,
sodium ferrocyanide ([Fe(CN)6]
4-), HEPES and other
chemicals were obtained from Sigma Chemical (St. Louis,
MO, USA). Krebs solution contained (in mM) 136 NaCl,
2.6 KCl, 1.8 CaCl2, and 10 HEPES at pH 7.0. All studies
were performed with approval of the Veterans Affairs
Institutional Animal Care and Use Committee (VA
IACUC). Male Sprague-Dawley rats weighing 200–250 g
(Harlan, San Diego, CA, USA) were fasted overnight, but
had free access to water.
Measurement of Duodenal HCO3
- Secretion
Duodenal loops were prepared and perfused as previously
described [16, 17]. Under isoﬂurane anaesthesia (2.0%),
the proximal duodenal loop (perfused length 2 cm) was
perfused with pH 7.0 Krebs buffer by using a peristaltic
pump (Fisher Scientiﬁc, Pittsburgh, PA, USA) at 1 ml/min.
The perfusate was bubbled with 100% O2, and stirred and
warmed at 37C with a heating stirrer (Barnstead Int.,
Dubuque, IA, USA). To eliminate the buffer action of
perfusing chemicals, which would over- or under-estimate
the titration volume using pH-stat, two sets of ﬂow-through
pH and CO2 electrodes (Lazar Lab, Los Angeles, CA) were
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123connected in the perfusion loop where pH and CO2 con-
centration ([CO2]) were simultaneously and continuously
measured. Since the input (perfusate) [CO2] is approxi-
mately zero, the efﬂuent [CO2] and pH were used to cal-
culate the total CO2 output equivalent to the secreted
HCO3
- as previously described [16, 17]. HCO3
- secretion
was expressed as total CO2 output (lmol/min/cm). The
efﬂuent was collected every 5 min in a sterilized tube on
ice for water output measurement as described below. After
stabilization with continuous perfusion of pH 7.0 Krebs for
about 30 min, the time was set as t = 0. The duodenal loop
was perfused with pH 7.0 Krebs from t = 0 min until
t = 10 min (basal period). The perfusate was then changed
to pH 7.0 Krebs buffer containing lubiprostone (0.1–
10 lM) or vehicle from t = 10 min until t = 35 min
(challenge period), with or without antagonists.
Measurement of Duodenal Cl
- Secretion
Cl
- concentration ([Cl
-]) in the duodenal efﬂuent was
measured using a ﬂow-through Cl
--selective electrode
(Lazar Lab), connected in series with the ﬂow-through
efﬂuent unit of CO2 electrode. A standard curve for Cl
-
solution (2.8, 28, 280 mM) was used to calculate the
efﬂuent [Cl
-]. Since perfusate [Cl
-] is stable, the perfusate
(input) [Cl
-] was measured separately using the same
electrode. Net Cl
- secretion was calculated by subtracting
the perfusate [Cl
-] from the efﬂuent [Cl
-] with adjustment
for water output, and expressed as net Cl
- output (lmol/
min/cm).
Measurement of Duodenal Water Flux
Waterﬂuxfromtheduodenalloopwasmeasuredwithanon-
absorbable,minimallybioreactivemarker[18],[Fe(CN)6]
4-
(10 mM), contained in the perfusate. [Fe(CN)6]
4- concen-
tration was measured by a spectrophotometer at 320 nm
absorbance. Water ﬂux was expressed as net water output
(ll/min/cm). Cl
- output was adjusted according to the cal-
culated water output.
Effect of Lubiprostone With or Without CFTR
Inhibition on HCO3
-,C l
-, and Water Output
In order to examine the effect of lubiprostone on duodenal
HCO3
- secretion, Cl
- secretion and water ﬂux, we ﬁrst
perfused lubiprostone (0.1, 1, or 10 lM) or vehicle in pH
7.0 Krebs buffer containing [Fe(CN)6]
4- (10 mM).
Some animals were pre-treated with the potent selective
CFTR inhibitor CFTRinh-172 (1 mg/kg, ip) 1 h prior to the
experiments. Pre-treatment with CFTRinh-172 at this con-
centration eliminates acid-induced HCO3
- secretion in rat
duodenum [15].
Role of the Prostaglandin Pathway in Lubiprostone-
Induced HCO3
- Secretion
We investigated the contribution of the prostaglandin (PG)
pathway involving cyclooxygenase (COX) and E-type
PG receptors (EP) towards lubiprostone-induced HCO3
-
secretion. Lubiprostone (10 lM) was co-perfused with an
EP1/EP2 receptor antagonist AH6809 (0.1 mM) or a potent
EP4 receptor antagonist AH23848 (0.1 mM). Some ani-
mals were pre-treated with the non-selective COX inhibitor
indomethacin (5 mg/kg, ip) 1 h prior to the experiments as
previously described [19].
Statistics
All data are expressed as means ± SEM. Data were
derived from six rats in each group. Comparisons between
groups were made by one-way ANOVA followed by
Fischer’s least signiﬁcant difference test. P values of 0.05
were taken as signiﬁcant.
Results
Effect of Lubiprostone on Duodenal Ion Secretion
Lubiprostone (0.1-10 lM) concentration-dependently
increased duodenal HCO3
- secretion in comparison with
the vehicle group (Fig. 1a). In contrast, net Cl
- output was
increased only by a low concentration (0.1 lM) of lubi-
prostone (Fig. 1b), accompanied by increased net water
output (Fig. 1c). This result demonstrated that a low con-
centration (0.1 lM) of lubiprostone affects Cl
- secretion,
whereas a high concentration (10 lM) stimulates HCO3
-
secretion. Lubiprostone may thus either reciprocally acti-
vate HCO3
- and Cl
- secretion, or augmented HCO3
-
secretion may mask stimulated Cl
- secretion.
Effect of CFTR Inhibition on Lubiprostone-Induced
Ion Secretion
We pretreated rats with CFTRinh-172 in order to examine
the function of CFTR in HCO3
- secretion in response to
perfusion of high concentration lubiprostone (10 lM).
CFTR inhibition reduced lubiprostone-induced HCO3
-
secretion (Fig. 2a), suggesting that lubiprostone-induced
HCO3
- secretion is partially CFTR-dependent. CFTR
inhibition had no effect on net Cl
- output (Fig. 2b).
Interestingly, CFTR inhibition decreased net water output
during the basal period, with lubiprostone perfusion
increasing net water output to the same level as measured
in the vehicle group (Fig. 2c). This result suggests that
Dig Dis Sci (2009) 54:2063–2069 2065
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water output.
In contrast, CFTR inhibition partially suppressed low
concentration lubiprostone (0.1 lM)-induced Cl
- output
(Fig. 3b), but had no effect on HCO3
- secretion (Fig. 3a).
Again,CFTRinhibitiondecreasednetwateroutputduringthe
basal period, and inhibited low concentration lubiprostone-
induced water output (Fig. 3c), suggesting that lubiprostone-
induced Cl
- secretion is partially CFTR-dependent.
Effect of EP Receptor Antagonist or COX Inhibition
on Lubiprostone-Induced HCO3
- Secretion
We next examined whether lubiprostone has PGE2 agonist-
like effects. Lubiprostone (10 lM)-induced HCO3
- secre-
tion was abolished by the co-perfusion of the potent EP4
receptor antagonist AH23848 (0.1 mM), whereas an EP1/
EP2 receptor antagonist AH6809 (0.1 mM) had no effect
(Fig. 4a). Furthermore, indomethacin pretreatment (5 mg/
kg, ip) had no effect on lubiprostone (10 lM)-induced
Fig. 1 Effect of lubiprostone on ion secretion in rat duodenum. a
Duodenal HCO3
- secretion was measured as total CO2 output using
pH and CO2 electrodes. b Cl
- secretion was measured with a
Cl
--selective electrode and expressed as net Cl
- output. c Water
secretion was measured using [Fe(CN)6]
4- as a non-absorbable
marker and expressed as net water output. Perfusion of lubiprostone
(0.1–10 lM) concentration dependently increased total CO2 output
(a), whereas only low concentration of lubiprostone (0.1 lM)
increased net Cl
- and water output (b, c). Data are expressed as
mean ± SEM (n = 6). * P\0.05 versus vehicle group
Fig. 2 Effect of CFTR inhibition on lubiprostone-induced HCO3
-
secretion in rat duodenum. a CFTR was inhibited by CFTRinh-172
(1 mg/kg, ip) 1 h prior to the experiment. Lubiprostone (10 lM)-
induced HCO3
- secretion was reduced by CFTR inhibition. b CFTR
inhibition had no effect on Cl
- secretion. c CFTR inhibition decreased
watersecretionandlubiprostonereversedtheeffectofCFTRinhibition.
Data are expressed as mean ± SEM (n = 6). * P\0.05 versus
vehicle group,
  P\0.05 versus lubiprostone group
2066 Dig Dis Sci (2009) 54:2063–2069
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- secretion (Fig. 4b). These results suggest that
lubiprostone may directly stimulate EP4 receptors,
increasing HCO3
- secretion, rather than activating COX.
Discussion
We demonstrated that luminally-perfused lubiprostone
increased ion secretion with a concentration-related
manner; a high concentration (10 lM) increased HCO3
-
secretion, whereas a low concentration (0.1 lM) increased
Cl
- and water secretion. Lubiprostone-induced HCO3
-
secretion was partially CFTR-dependent, whereas Cl
-
secretion was not apparently CFTR-dependent, presumably
involving non-CFTR mediated Cl
- secretion. High con-
centration lubiprostone may directly stimulate EP4 recep-
tors, increasing duodenal HCO3
- secretion. CFTR
inhibition decreased net water output, reversed by a high or
low concentration of lubiprostone, consistent with CFTR-
independent Cl
- secretion. This is the ﬁrst study demon-
strating that lubiprostone stimulates duodenal ion secretion
in vivo. Furthermore, lubiprostone may act as a dual acti-
vator of CFTR-independent Cl
- secretion and as a PG
receptor agonist.
The mechanism by which lubiprostone stimulates
intestinal Cl
- secretion selectively via ClC-2 is contro-
versial. Lubiprostone activates ClC-2 via a CFTR-inde-
pendent mechanism in T84 cells [1]. In Ussing-chambered
ileum and colon, lubiprostone increases Cl
- secretion by a
CFTR-independent mechanism [13]. Furthermore, the
localization of ClC-2 in the intestinal epithelial cells is also
controversial. Transfected T84 and MDCK cells express
Fig. 3 Effect of CFTR inhibition on lubiprostone-induced Cl
-
secretion in rat duodenum. CFTR inhibition tended to decrease
lubiprostone (0.1 lM)-induced Cl
- secretion (b), but had no effect on
HCO3
- secretion (a). Lubiprostone reversed CFTR inhibition-
induced decrease of water output (c). Data are expressed as
mean ± SEM (n = 6). * P\0.05 versus vehicle group,
  P\0.05
versus lubiprostone group
Fig. 4 Effect of prostaglandin receptor antagonist and cyclooxygen-
ase inhibitor on lubiprostone-induced HCO3
- secretion in rat
duodenum. a AH6809 (0.1 mM) had no effect on lubiprostone
(10 lM)-induced HCO3
- secretion, whereas AH23848 (0.1 mM)
abolished the effect of lubiprostone. Data are expressed as mean ±
SEM (n = 6). * P\0.05 versus vehicle group,
  P\0.05 versus
lubiprostone group. b Indomethacin (Indo, 5 mg/kg, sc) was given 1 h
prior to the experiment. Indomethacin pretreatment had no effect on
lubiprostone (10 lM)-induced HCO3
- secretion. Data are expressed
as mean ± SEM (n = 6). * P\0.05 versus vehicle group
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tochemistry on intact intestinal sections reveals the
expression of ClC-2 on the enterocyte basolateral mem-
brane [6, 20] or in the region of the intercellular tight
junctions [4]. Since the duodenum secretes Cl
- and
HCO3
- via a CFTR-dependent mechanism, whereas ClC-2
is localized on the basolateral membrane of duodenocytes
[6], we assessed the involvement of CFTR in duodenal
lubiprostone-induced ion secretion. Our results demon-
strated that at high concentration, lubiprostone stimulated
HCO3
- secretion via a CFTR-dependent mechanism,
whereas a low concentration increased Cl
- secretion via a
CFTR-independent mechanism.
Furthermore, the site of lubiprostone action is still con-
troversial. Since lubiprostone is derived from PGE1 [21], it
may activate EP receptors. Indeed, EP receptor antagonists
diminished lubiprostone-induced contraction of rat gastric
and colonic smooth muscle with an apparent pKB of 6.7–7.6
[22]. In contrast, the lubiprostone-induced Isc increase in
guinea pig colon was not affected by EP receptor antago-
nists [13]. Our results show that high concentration lubi-
prostone-induced HCO3
- secretion is mediated via the EP4
receptor, but not via EP1/EP2 or endogenous PGs by COX
activation. Since EP4 activation increases intracellular
cAMP [23], and elevated cAMP activates CFTR [24],
CFTR-dependent HCO3
- secretion by lubiprostone is
consistent with EP4 receptor activation by lubiprostone.
Taken together, our results support the hypothesis that
high concentration lubiprostone directly stimulates EP4
receptors, activating CFTR and increasing HCO3
- secre-
tion in rat duodenum. Existing controversies regarding the
CFTR dependence of lubiprostone action might reﬂect
species, intestinal segment, and concentration differences.
Our results also support the hypothesis that low concen-
tration lubiprostone activates Cl
- secretion via non-CFTR
channels. Unfortunately, the lack of selective ClC-2 inhib-
itors impedes further characterization of the mechanism by
which low concentration lubiprostone augments Cl
-
secretion. Very recent data generated from mucosal biop-
sies obtained from normal mice and humans and those
homozygous for CFTR loss-of-function mutations, and
CFTR null mice strongly implicated the CFTR in lubipro-
stone-stimulated anion secretion. Furthermore, this secre-
tion was signiﬁcantly reduced by EP4 receptor antagonists,
as is consistent with our data [25].
Increased duodenal HCO3
- secretion induced by a high
concentration of lubiprostone (10 lM) may protect the
mucosa from acid-induced injury. Although the exact
luminal concentration of lubiprostone in humans is not
available, the recommended dose (24 lg; *60 nmol) may
produce duodenal luminal concentrations to the dose we
tested (10 nmol/min). Since duodenal luminal concentra-
tions are no doubt higher than in the distal gut, the 24 lg
dose may protect the gastroduodenal mucosa. In the distal
gut, the lower lubiprostone concentrations may increase
Cl
- secretion.
CFTR inhibition decreased water output, presumably
explained by the reciprocal activation of Na
?/H
? exchan-
ger-3 (NHE3) on the apical membrane [26] mediating Na
?
absorption followed by water absorption. Recovery of
water output by low concentration lubiprostone during
CFTR inhibition is consistent with CFTR-independent Cl
-
secretion. ClC-2 channels, due to their basolateral location
in the duodenum, may increase duodenal Cl
- absorption
during HCO3
- secretion as an alternative to CFTR-medi-
ated Cl
- recycling across the apical membrane. Further-
more, lubiprostone stimulates CFTR-dependent HCO3
-
secretion without changing net Cl
- secretion. This effect
supports the hypothesis that Cl
- secreted by CFTR is
recycled across the apical membrane by anion exchangers.
Interestingly, the non-speciﬁc anion exchange inhibitor
DIDS inhibits lubiprostone-induced Isc increase in guinea
pig ileum [13], also supporting this hypothesis.
CFTR-dependent and -independent actions of lubipro-
stone may be beneﬁcial for other organs, which manifest
the CF phenotype. Recently, lubiprostone was reported to
increase Isc and mucus secretion via CFTR-dependent
and -independent pathways in airway submucosal glands,
suggesting it might be of beneﬁt outside of the gastroin-
testinal tract [27].
In conclusion, lubiprostone stimulates duodenal HCO3
-
and Cl
- secretion via different pathways, dependent on its
concentration. Increased duodenal HCO3
- secretion sug-
gests that lubiprostone may protect the duodenum from
acid-induced injury. Restoration of impaired water output
during CFTR inhibition suggests that lubiprostone may
improve the intestinal phenotype in CF patients.
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